Posted by Michael Wonder on 02 Jul 2018
Dermira receives FDA approval for Qbrexza (glycopyrronium) cloth to treat primary axillary hyperhidrosis
29 June 2018 - Qbrexza is expected to be available for prescribing in October 2018.
Dermira announced today that the U.S. FDA has approved Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and paediatric patients 9 years of age and older.
The approval is based on results from two Phase 3 clinical trials, ATMOS-1 and ATMOS-2, which evaluated the efficacy and safety of Qbrexza in patients with primary axillary hyperhidrosis.
